A study presented results from a week 16 analysis of tildrakizumab, an interleukin-23 inhibitor, for the treatment of moderate to severe plaque psoriasis of the scalp. Results showed that a significantly higher proportion of patients treated with tildrakizumab achieved clearance of their scalp psoriasis compared to placebo. Adverse events were reported more in the tildrakizumab group. The study concluded that tildrakizumab is efficacious in treating scalp psoriasis with improvements in patient-reported scalp itch and quality of life, and no new safety signals were identified. Scalp psoriasis is a common condition affecting a large percentage of patients with psoriasis.
Source link
Tildrakizumab proves effective as treatment for scalp psoriasis
